In parallel, novel HF biomarkers such as soluble interleukin 1 receptor-like 1 (ST-2), have emerged as complementary prognostic indicators, reflecting not only the hemodynamic status in HF patients, but also their inflammatory and pro-fibrotic response (10, 11). This evidence concerns the gene IL1RL1 and hydrops fetalis.